Drug Profile
Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience
Alternative Names: AD-0802; AD-1502; AD-2203; AE-1501; BAN-2203; BAN-2502; BAN2401 back-upLatest Information Update: 18 Nov 2022
Price :
$50
*
At a glance
- Originator BioArctic Neuroscience
- Developer BioArctic
- Class Antidementias; Antiparkinsonians; Monoclonal antibodies; Vaccines
- Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 14 Nov 2022 The US PTO grants a new platform patent for a technology for transporting biopharmaceuticals across the blood-brain barrier in USA
- 28 Oct 2022 No recent reports of development identified for research development in Parkinson's-disease in Sweden (Parenteral)
- 20 Apr 2022 AbbVie terminated the collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV 0805